Cautious. AZN's 58.5 Growth Compounder Score reflects solid operational momentum, but a 49 Value score and 83 Vulnerability Index signal material headwinds. Pipeline replacement risk is the core concern—patent cliffs on legacy franchises require successful late-stage asset advancement. Leadership alignment at 62.5 is adequate but not exceptional; management's execution on R&D productivity will be decisive. Wide moat in oncology/specialty care provides downside protection, yet the company trades
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for ASTRAZENECA PLC ORD SHS $0.25:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 59/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates ASTRAZENECA PLC ORD SHS $0.25 (AZN.L) at 59/100 — below the bar Stocky looks for. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Cautious. AZN's 58.5 Growth Compounder Score reflects solid operational momentum, but a 49 Value score and 83 Vulnerability Index signal material headwinds. Pipeline replacement risk is the core concern—patent cliffs on legacy franchise
AZN.L's current Stocky Verdict is 59/100, placing it in the "Cautious" band. This composite combines a 59/100 Compounder score, 63/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for ASTRAZENECA PLC ORD SHS $0.25 yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
ASTRAZENECA PLC ORD SHS $0.25 scores 63/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
ASTRAZENECA PLC ORD SHS $0.25's Vulnerability Profile scores 83/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to ASTRAZENECA PLC ORD SHS $0.25.
Sign up free and unlock the full analysis on AZN.L — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
Or jump straight to the interactive dashboard for AZN.L in the app.
